MD vs THC: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
THC is the larger of the two ($21.52B market cap): the incumbent the market prices for continued execution (12.68x forward earnings, beta 1.20). MD is the smaller challenger ($2.22B), priced similarly on forward earnings (11.22x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
MD vs THC: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | MD | THC | What it tells you |
|---|---|---|---|
| Market cap | $2.22B | $21.52B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 11.22 | 12.68 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 13.10 | 10.33 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.61 | 1.20 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 95% of range | 87% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.46 | 4.62 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how MD and THC affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MD and THC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MD and THC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Pediatrix Medical Group (MD) do?
Pediatrix Medical Group (NYSE: MD), founded in 1979 and known as MEDNAX until its 2022 rebrand, provides hospital-based physician staffing and clinical services concentrated in neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and related anesthesiology support. Its clinicians largely staff neonatal intensive care units and other hospital departments under contracts with hospital partners, with revenue driven by patient volumes, payer reimbursement, contract administrative fees and revenue-cycle collections.
What does Tenet Healthcare (THC) do?
Tenet Healthcare is a diversified for-profit healthcare services company that operates through three segments. Hospital Operations runs acute care and specialty hospitals plus affiliated outpatient facilities, imaging centers, and physician practices. United Surgical Partners International (USPI) is the ambulatory segment and operates or holds interests in hundreds of ambulatory surgery centers and surgical hospitals across dozens of states, making it the largest ASC platform in the country. Conifer Health Solutions provides revenue cycle management and value-based care services to hospitals and health systems.
MD vs THC: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- MD drivers: Pricing and reimbursement strength; Portfolio simplification and debt paydown.
- THC drivers: USPI ambulatory surgery leadership; Business mix shift toward higher-margin services.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Portfolio restructuring and practice divestitures continue to pressure headline revenue and narrow revenue diversification in a sector with several large, well-capitalized competitors. For THC, hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix.
MD or THC: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MD if you believe its drivers more; THC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MD and THC guides.
MD vs THC: the full fundamentals
MD. Pediatrix trades near 13x trailing earnings, still below the roughly 20x-plus average for healthcare-services peers, though the stock's roughly 29% gain in 2026 has narrowed the gap. Q2 2026 revenue rose about 4.1% year on year to roughly $488 million and adjusted EPS of $0.63 beat consensus, with full-year adjusted EBITDA guidance held near $290 million at the midpoint. Third-quarter results on November 2, 2026 carry a consensus near $0.65 EPS on about $498 million of revenue.
THC. Tenet still trades at a modest earnings multiple typical of hospital operators (a discount that prices in reimbursement and leverage risk), even after a 35% rise in 2026 as USPI mix shift, margin gains, and deleveraging improved earnings quality. The forward P/E near 13x sits above the trailing figure because analysts expect 2027 EPS of about $21, roughly flat with 2026, after a run of large beats. Third-quarter results on October 29, 2026 will show whether the outperformance continues.
Headline figures (approximate, October 2026): MD shows revenue (ttm) ~$1.95B, up ~4% year over year in Q2 2026, q2 2026 net revenue ~$488M, net margin (ttm) ~9%, net income ~$175M, eps (ttm / forward) ~$2.09 / ~$2.44; THC shows revenue (ttm) ~$21.8 billion (Q2 2026 +~7% yoy), q2 2026 adjusted eps ~$6.12 vs ~$4.26 est., net income (ttm) ~$2.24 billion (net margin ~10%), operating margin (ttm) ~18%.
The bottom line: MD vs THC
MD and THC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MD and THC exposure against your real portfolio. It is not an investment adviser.
Wondering how MD or THC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Pediatrix Medical Group with AI
Connect the broker you already use and ask Walnut's AI how MD fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between MD and THC?
+
Pediatrix Medical Group (NYSE: MD), founded in 1979 and known as MEDNAX until its 2022 rebrand, provides hospital-based physician staffing and clinical services concentrated in neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and related anesthesiology support. Tenet Healthcare is a diversified for-profit healthcare services company that operates through three segments. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is MD or THC the better stock?
+
Neither is universally better. THC is the larger incumbent; MD is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, MD or THC?
+
On forward P/E (as of October 2026), MD trades at 11.22x and THC at 12.68x, so MD is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both MD and THC?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of MD vs THC?
+
MD: Portfolio restructuring and practice divestitures continue to pressure headline revenue and narrow revenue diversification in a sector with several large, well-capitalized competitors. Physician compensation, salaries and staffing costs can squeeze already tight margins if pricing gains slow. Patient volumes have been declining in parts of the business, including maternal-fetal medicine and neonatology, so growth leans heavily on pricing and payer mix rather than demand. The business is exposed to government and commercial reimbursement policy, hospital-contract renewals and concentration in a small set of subspecialties. Any reversal in payer mix or collections would hit results quickly given the thin operating margins. After a 70% one-year gain the shares trade above the mean analyst target with a consensus hold rating, and consensus for the September 2026 quarter calls for EPS of about $0.65, roughly 3% below a year earlier, so expectations leave less cushion than they did at the start of 2026. The balance sheet carries about $620 million of debt against roughly $404 million of cash. THC: Hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. Labor costs, physician and nurse staffing, and wage inflation weigh on the hospital segment. The company still carries meaningful debt despite deleveraging, so higher-for-longer interest rates matter. Bad debt from uninsured and underinsured patients, regulatory and billing scrutiny, and cyclicality in elective surgical volumes are additional risks. Acquisition-led USPI growth depends on continued access to attractive surgery-center deals at reasonable prices. After a roughly 35% gain in 2026, expectations are higher too: consensus calls for 2027 EPS of about $21.08, slightly below the roughly $21.22 expected for 2026, so the market is not pricing in another year of rapid earnings growth, and a stumble against that bar could weigh on the shares.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell MD or THC; figures are approximate and dated (as of October 2026). Verify current data before investing.